Retrospective Determination of Prognostic Factors in BRAF- V600E Melanoma Brain Metastases
Lily Erickson, Sahana Ramaswamy, Sherise Ferguson, James Long, Hussein Tawbi, Merve Hasanov, Alicia Bea Davies, Elizabeth Sirmans, Chantal Saberian, Eliza L. Posada, Jared Malke, Lauren Haydu, Caroline Chung
Results • 97 different treatment sequences represented in 100 patients (Fig. 1) • Gender not associated with differences in OS (Log rank, p=0.91051) 2 • Initial treatment with immunotherapy (IT) did not demonstrate survival advantage to initial targeted therapy (TT) (Log rank, p=0.57813) 3 • Breakthrough BM (develop despite ongoing systemic therapy at time of diagnosis) did not show OS difference compared to non-breakthrough cases (Fig. 2a) • Non-breakthrough cases were associated with a survival advantage compared to breakthrough cases for those who received initial TT or IT (Fig. 2b)
Breakthrough vs. Non-Breakthrough: All Cases
Breakthrough vs. Non-Breakthrough: System Therapy Initial
(a)
(b)
(d)
(d)
Fig. 1. Treatment flow diagram demonstrating sequence of various treatments and diagnosis. The open circle represents primary melanoma diagnosis. The closed circle represents death or end of study period. The weight of each line is proportionate to the number of patients represented.
MD ANDERSON CANCER CENTER Fig. 2. (a) Kaplan Meier curve showing OS comparison for all breakthrough vs. non-breakthrough cases. (b) Kaplan Meier curve showing OS comparison for breakthrough vs. non-breakthrough cases where patient received initial BM therapy of immunotherapy or targeted therapy.
Made with FlippingBook - PDF hosting